The race to target the remaining RAS mutants continues, with over 24 clinical and 70 pre-clinical stage programs striving for first- and best-in-class. Now more than ever, we are witnessing this growing industry make strides to utilize novel modalities and elucidate mechanisms of resistance – making treating patients with RAS mutant cancers beyond NSCLC not just a possibility, but a reality.

As the leading industry-centered forum, the 6th RAS-Targeted Drug Development Summit 2024 returns to Boston this September and is once again dedicated to every aspect of discovery and development of RAS therapies, from discovery through to clinical development, to create effective frontline RAS therapies for cancer and better patient outcomes.

Over three jam-packed days, 38+ leading stakeholders will exhibit breakthrough novel data, latest clinical advancements, proof-of-concept, and strategic perspectives, all armed to improve the standard of care for patients in need.

This year’s summit will tackle some of the hottest advances and burning questions in the space, such as:

• Targeting more mutants with RAS(ON) form, pan-RAS approaches, and non-canonical targets to combat cancers beyond NSCLC
• Defeating intrinsic or acquired mechanistic resistance and reducing off-target effects to ensure more effective RAS-directed medicines reach the patient
• Showcasing vaccines, cell therapies, monovalent and heterobifunctional modalities with improved selectivity and potency to avoid cancer recurrence
• Investigating valuable combination approaches utilizing inhibitors of up- and downstream high-value targets such as SOS1, MEK, RAF, and ERK

Join 200+ of your biopharma and academic peers from Early Discovery, Translational Oncology, and Clinical Development at the unrivaled end-to-end forum as we foster critical conversations and navigate cutting-edge treatments – empowering the developers of RAS-targeted therapies to make a positive impact on the future of cancer treatment. Join us as we work together to create effective frontline RAS therapies for better patient outcomes.

To know more visit: https://ter.li/hosjv6